The PMI Predictor - a Web App Enabling Green-by-Design Chemical Synthesis
暂无分享,去创建一个
David K. Leahy | Martin D. Eastgate | J. Gage | A. Wells | E. Sherer | F. Gallou | F. Roschangar | J. Albrecht | Jun Li | M. Kopach | Barry. R. Dillon | S. Koenig | I. Martínez | M. Olbrich | Jared L. Piper | L. Diorazio | Alina Borovika | Christiana Briddell
[1] V. Veleva,et al. Benchmarking Green Chemistry Adoption by the Global Pharmaceutical Supply Chain , 2018 .
[2] John D. Hayler,et al. Inspiring process innovation via an improved green manufacturing metric: iGAL , 2018 .
[3] Julie B. Zimmerman,et al. The Green ChemisTREE: 20 years after taking root with the 12 principles , 2018 .
[4] John Andraos,et al. Useful Tools for the Next Quarter Century of Green Chemistry Practice: A Dictionary of Terms and a Data Set of Parameters for High Value Industrial Commodity Chemicals , 2018 .
[5] Jun Li,et al. Evolving Green Chemistry Metrics into Predictive Tools for Decision Making and Benchmarking Analytics , 2018 .
[6] V. Veleva,et al. Benchmarking green chemistry adoption by “big pharma” and generics manufacturers , 2017 .
[7] F. Gosselin,et al. Development of a Practical Synthesis of ERK Inhibitor GDC-0994 , 2017 .
[8] Michael A. Schmidt,et al. On the design of complex drug candidate syntheses in the pharmaceutical industry , 2017 .
[9] John D. Hayler,et al. A deeper shade of green: inspiring sustainable drug manufacturing , 2017 .
[10] Jun Li,et al. A data-driven strategy for predicting greenness scores, rationally comparing synthetic routes and benchmarking PMI outcomes for the synthesis of molecules in the pharmaceutical industry , 2017 .
[11] Wei Zhang,et al. A Robust Kilo-Scale Synthesis of Doravirine , 2016 .
[12] John L Tucker,et al. Industrial research: Drug companies must adopt green chemistry , 2016, Nature.
[13] A. L. Frederick,et al. Synthesis of BACE Inhibitor LY2886721. Part I. An Asymmetric Nitrone Cycloaddition Strategy , 2015 .
[14] M. Langston,et al. Process Development and GMP Production of a Potent NAE Inhibitor Pevonedistat , 2015 .
[15] David K. Leahy,et al. Control Strategy for the Manufacture of Brivanib Alaninate, a Novel Pyrrolotriazine VEGFR/FGFR Inhibitor , 2015 .
[16] Jun Li,et al. Current complexity: a tool for assessing the complexity of organic molecules. , 2015, Organic & biomolecular chemistry.
[17] Roger A. Sheldon,et al. Overcoming barriers to green chemistry in the pharmaceutical industry – the Green Aspiration Level™ concept , 2015 .
[18] I. Mangion. Enantioselective Synthesis of an HCV NS5a Antagonist (I). , 2014 .
[19] Steven H. Chan,et al. Development of a Continuous Plug Flow Process for Preparation of a Key Intermediate for Brivanib Alaninate , 2014 .
[20] Melodie Christensen,et al. Enantioselective synthesis of an HCV NS5a antagonist. , 2014, Organic letters.
[21] T. LaPorte,et al. Commercial Synthesis of a Pyrrolotriazine–Fluoroindole Intermediate to Brivanib Alaninate: Process Development Directed toward Impurity Control , 2014 .
[22] Stuart H. Taylor,et al. Synthesis of Filibuvir. Part I. Diastereoselective Preparation of a β-Hydroxy Alkynyl Oxazolidinone and Conversion to a 6,6-Disubstituted 2H-Pyranone , 2014 .
[23] Melvin J. Yu,et al. From micrograms to grams: scale-up synthesis of eribulin mesylate. , 2013, Natural product reports.
[24] Chunrong Ma,et al. Development of a Practical Synthesis of a TORC1/2 Inhibitor: A Scalable Application of Memory of Chirality , 2013 .
[25] Paul N. Devine,et al. Convergent Kilogram-Scale Synthesis of Dual Orexin Receptor Antagonist , 2013 .
[26] M. Schnaderbeck,et al. Process Development of Halaven®: Synthesis of the C1–C13 Fragment from d-(–)-Gulono-1,4-lactone , 2013, Synlett.
[27] Ian A. Watson,et al. Complexity-Based Metric for Process Mass Intensity in the Pharmaceutical Industry , 2013 .
[28] M. Kubota,et al. Process Development of Halaven®: Synthesis of the C14–C35 Fragment via Iterative Nozaki–Hiyama–Kishi Reaction–Williamson Ether Cyclization , 2013 .
[29] M. Kubota,et al. Commercial Manufacture of Halaven®: Chemoselective Transformations En Route to Structurally Complex Macrocyclic Ketones , 2013, Synlett.
[30] F. Gosselin,et al. A Practical Synthesis of a PI3K Inhibitor under Noncryogenic Conditions via Functionalization of a Lithium Triarylmagnesiate Intermediate , 2013 .
[31] S. Yoshida,et al. Development of a Practical and Scalable Synthesis of a Potent Selective Dual Antagonist for 5-HT2B and 5-HT7 Receptors , 2012 .
[32] J. Moseley,et al. Process Development and Scale-Up of AZD7545, a PDK Inhibitor , 2012 .
[33] D. Entwistle,et al. Route Selection and Process Development of a Multikilogram Route to the Inhaled A2a Agonist UK-432,097 , 2012 .
[34] T. A. Ayers,et al. Scale-Up of an Enantioselective Overman Rearrangement for an Asymmetric Synthesis of a Glycine Transporter 1 Inhibitor , 2012 .
[35] D. Entwistle,et al. Development of a Scaleable Synthesis of a Geminal Dimethyl Tertiary Amine as an Inhaled Muscarinic Antagonist for the Treatment of COPD , 2012 .
[36] William J. W. Watson,et al. How do the fine chemical, pharmaceutical, and related industries approach green chemistry and sustainability? , 2012 .
[37] Roger A. Sheldon,et al. The E Factor: fifteen years on , 2007 .
[38] Hadley Wickham,et al. Reshaping Data with the reshape Package , 2007 .
[39] Nhan Nguyen,et al. “Green engineering: Defining the principles”— resdts from the sandestin conference , 2003 .
[40] David J. C. Constable,et al. Metrics to ‘green’ chemistry—which are the best? , 2002 .
[41] P. Anastas,et al. Green Chemistry , 2018, Environmental Science.